X4 Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 35.34
| XFOR Stock | USD 0.76 0.09 13.54% |
XFOR |
X4 Pharmaceuticals Target Price Odds to finish over 35.34
The tendency of XFOR Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 35.34 or more in 90 days |
| 0.76 | 90 days | 35.34 | close to zero percent |
Based on a normal probability distribution, the odds of X4 Pharmaceuticals to move over $ 35.34 or more in 90 days from now is close to zero percent (This X4 Pharmaceuticals probability density function shows the probability of XFOR Stock to fall within a particular range of prices over 90 days) . Probability of X4 Pharmaceuticals price to stay between its current price of $ 0.76 and $ 35.34 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days X4 Pharmaceuticals has a beta of 0.0215. This entails as returns on the market go up, X4 Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding X4 Pharmaceuticals will be expected to be much smaller as well. Additionally X4 Pharmaceuticals has an alpha of 0.6731, implying that it can generate a 0.67 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). X4 Pharmaceuticals Price Density |
| Price |
Predictive Modules for X4 Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as X4 Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.X4 Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. X4 Pharmaceuticals is not an exception. The market had few large corrections towards the X4 Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold X4 Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of X4 Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.67 | |
β | Beta against Dow Jones | 0.02 | |
σ | Overall volatility | 0.12 | |
Ir | Information ratio | 0.05 |
X4 Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of X4 Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for X4 Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| X4 Pharmaceuticals is way too risky over 90 days horizon | |
| X4 Pharmaceuticals has some characteristics of a very speculative penny stock | |
| X4 Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| X4 Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (101.17 M) with profit before overhead, payroll, taxes, and interest of 3 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (96.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| X4 Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting Exposition |
X4 Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of XFOR Stock often depends not only on the future outlook of the current and potential X4 Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. X4 Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 177.8 M | |
| Cash And Short Term Investments | 114.2 M |
X4 Pharmaceuticals Technical Analysis
X4 Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. XFOR Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of X4 Pharmaceuticals. In general, you should focus on analyzing XFOR Stock price patterns and their correlations with different microeconomic environments and drivers.
X4 Pharmaceuticals Predictive Forecast Models
X4 Pharmaceuticals' time-series forecasting models is one of many X4 Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary X4 Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about X4 Pharmaceuticals
Checking the ongoing alerts about X4 Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for X4 Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| X4 Pharmaceuticals is way too risky over 90 days horizon | |
| X4 Pharmaceuticals has some characteristics of a very speculative penny stock | |
| X4 Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| X4 Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (101.17 M) with profit before overhead, payroll, taxes, and interest of 3 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (96.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| X4 Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting Exposition |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.